Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Mol Cancer Ther. 2019 Jun 18;18(9):1506–1519. doi: 10.1158/1535-7163.MCT-18-0571

Figure 3: AD80 significantly improves survival in a pre-clinical HCC model through enhanced inhibition of the ERK/MAPK pathway.

Figure 3:

A. Mouse survival in a HUH7 xenograft model. B. AD80 treated animals show a tumor growth rate that is half of vehicle treated animals, and significantly less than sorafenib treated animals. C. Western blot analysis of individual tumors harvested from animals at the end of the survival experiment shown in D. Note that mice that survived longest in D displayed relatively weak phospho-ERK1/2 signal compared to mice that died early. Antibodies used: S6 Ribosomal Protein(S6RP) (5G10), phospho-S6 Ribosomal Protein(S6RP) (Ser235/236, Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204), p44/42 MAPK (Erk1/2) (137F5). Blots were run in duplicate; representative data is shown.